Stocks and Investing
Stocks and Investing
Thu, June 27, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mohit Bansal Maintained (BMRN) at Buy with Increased Target to $115 on, Jun 27th, 2024
Mohit Bansal of Wells Fargo, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Increased Target from $110 to $115 on, Jun 27th, 2024.
Mohit has made no other calls on BMRN in the last 4 months.
There are 7 other peers that have a rating on BMRN. Out of the 7 peers that are also analyzing BMRN, 4 agree with Mohit's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Joel Beatty of "Baird" Downgraded from Buy to Hold and Decreased Target to $72 on, Friday, May 17th, 2024
- Whitney Ijem of "Canaccord Genuity" Maintained at Hold with Decreased Target to $89 on, Friday, April 26th, 2024
- David Lebovitz of "Citigroup" Maintained at Hold with Decreased Target to $91 on, Thursday, April 25th, 2024
- George Farmer of "Scotiabank" Maintained at Hold with Increased Target to $85 on, Thursday, April 25th, 2024
These are the ratings of the 3 analyists that currently disagree with Mohit
- Cory Kasimov of "Evercore ISI Group" Initiated at Buy and Held Target at $113 on, Tuesday, May 14th, 2024
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $112 on, Friday, April 26th, 2024
- Olivia Brayer of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $110 on, Thursday, April 25th, 2024
Contributing Sources